April 30thCrashbandicootclashofthetitansZhenbao Island released its 2023 annual report, which shows that the company achieved operating income of 31% in 2023.CrashbandicootclashofthetitansThe net profit of shareholders belonging to listed companies reached 473 million yuan, an increase of 154.93 percent over the same period last year. In addition, the company's pharmaceutical industry revenue increased by 84.79% compared with the same period last year. Under the background of intensified competition in the pharmaceutical industry, the important financial indicators show a considerable growth trend.

Combined with the revenue performance and net profit growth data of Zhenbao Pharmaceutical Industry, with the continuous upgrading of marketing strategy, the company's drug marketing level improved significantly in 2023. Thanks to the company's deepening marketing model optimization, sales of the core products Xuesaitong for injection, Shuxuening injection and Yanhuning for injection increased by 59.78%, 25.07% and 72.04% compared with the same period last year.

According to the Zhenbao Island Annual report, in 2023, the company deepens its marketing service strategy, ensures the comprehensiveness and quality of sales services, focuses on improving customer satisfaction, strengthens supply service, after-sales service, and brand academic promotion, and promotes development with services. continue to optimize and improve marketing service capabilities. Rely on the full-terminal differentiation market development strategy to optimize the national marketing network layout. Through the systematic integration of marketing resources, improve the overall planning of the headquarters, in-depth layout of three major terminals and six major markets, while mining the terminal value of the potential stock market, accelerate the expansion of new channels and new terminals. And actively promote hospital preparations, API projects, cultivate new business growth points.

In addition, the company combines industry policies, market development trends, market and clinical needs and other internal and external environment, continue to sell products marketing structure, based on modern and sustainable development. The pipeline layout of proprietary Chinese medicine products was optimized and expanded, and the product system with Xuesaitong injection, Yanhuning injection, Shuxuening injection, Xueshuantong capsule, compound Qinlan oral liquid and Shuanghuanglian preparation as the core was constructed. At the same time, combined with the development trend of epidemiology and evidence-based medicine, relying on marketing prediction and market measurement model, combined with variety field, technical pipeline, operation mode and other aspects to carry out variety mergers and acquisitions. During the reporting period, the company introduced nine clinical advantage varieties in respiratory system medication, digestive tract and metabolic system medication and other major treatment areas, all of which are in the national medical insurance catalogue, including Yinzhihuang tablets, Duyiwei granules, compound Banlangen granules, etc. during the reporting period, the change of drug marketing license holder has been completed, the variety sequence of the company has been improved, and the product pipeline has been enriched. Provide products with high quality and clinical core competitiveness for marketing.

An investment institution analyst believes that in recent years, with the continuous release of favorable policies, the rigid demand attribute of traditional Chinese medicine varieties continues to strengthen. At the same time, with the continuous optimization of the industrial structure of the pharmaceutical industry, the performance of proprietary Chinese medicine enterprises with strong brand influence and large varieties will rise steadily. Although the revenue of China's pharmaceutical manufacturing industry continued to decline in 2023 due to economic fluctuations, narrowing domestic demand and rising costs of traditional Chinese medicine, under this background, Zhenbao Island's net profit and revenue of the pharmaceutical industry still showed considerable growth, which will undoubtedly inject a shot into the fluctuating pharmaceutical market, and its profitability will also be further improved, forming a virtuous circle for the company to achieve high-quality development.

(article source: blue Whale Finance)